Lebwohl MG - Search Results

1

Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.

Genovese MC, Mysler E, Tomita T, Papp KA, Salvarani C, Schwartzman S, Gallo G, Patel H, Lisse JR, Kronbergs A, Leage SL, Adams DH, Xu W, Marzo-Ortega H, Lebwohl MG. Genovese MC, et al. Among authors: lebwohl mg. Rheumatology (Oxford). 2020 Dec 1;59(12):3834-3844. doi: 10.1093/rheumatology/keaa189. Rheumatology (Oxford). 2020. PMID: 32449924 Free PMC article.

2

Psoriasis.

Lebwohl M. Lebwohl M. Lancet. 2003 Apr 5;361(9364):1197-204. doi: 10.1016/S0140-6736(03)12954-6. Lancet. 2003. PMID: 12686053 Review.

3

A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.

Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D; Efalizumab Study Group. Lebwohl M, et al. N Engl J Med. 2003 Nov 20;349(21):2004-13. doi: 10.1056/NEJMoa030002. N Engl J Med. 2003. PMID: 14627785 Free article. Clinical Trial.

4

Relapse, rebound, and psoriasis adverse events: an advisory group report.

Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, Papp K, Rundle AC, Toth D. Carey W, et al. J Am Acad Dermatol. 2006 Apr;54(4 Suppl 1):S171-81. doi: 10.1016/j.jaad.2005.10.029. J Am Acad Dermatol. 2006. PMID: 16488339 Review.

5

Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I.

Pariser DM, Gordon KB, Papp KA, Leonardi CL, Kwon P, Compton PG, Rundle AC, Walicke PA, Lebwohl M. Pariser DM, et al. J Cutan Med Surg. 2005 Dec;9(6):303-12. doi: 10.1007/s10227-005-0116-1. J Cutan Med Surg. 2005. PMID: 16699904 Review.

6

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators. Papp KA, et al. Lancet. 2008 May 17;371(9625):1675-84. doi: 10.1016/S0140-6736(08)60726-6. Lancet. 2008. PMID: 18486740 Clinical Trial.

7

New biologics for psoriasis and psoriatic arthritis.

Rozenblit M, Lebwohl M. Rozenblit M, et al. Dermatol Ther. 2009 Jan-Feb;22(1):56-60. doi: 10.1111/j.1529-8019.2008.01216.x. Dermatol Ther. 2009. PMID: 19222517 Review.

8

Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation.

Menon K, Van Voorhees AS, Bebo BF Jr, Gladman DD, Hsu S, Kalb RE, Lebwohl MG, Strober BE; National Psoriasis Foundation. Menon K, et al. Among authors: lebwohl mg. J Am Acad Dermatol. 2010 Feb;62(2):291-9. doi: 10.1016/j.jaad.2009.03.047. Epub 2009 Jul 31. J Am Acad Dermatol. 2010. PMID: 19646777 Review.

9

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.

Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, Krueger GG. Lebwohl M, et al. Br J Dermatol. 2010 Jan;162(1):137-46. doi: 10.1111/j.1365-2133.2009.09491.x. Epub 2009 Nov 9. Br J Dermatol. 2010. PMID: 19903183 Clinical Trial.

10

Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations.

Lebwohl M, Yeilding N, Szapary P, Wang Y, Li S, Zhu Y, Reich K, Langley RG, Papp KA. Lebwohl M, et al. J Am Acad Dermatol. 2010 Oct;63(4):571-9. doi: 10.1016/j.jaad.2009.11.012. J Am Acad Dermatol. 2010. PMID: 20599293 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

690 results

Search Page